AlloVir Announces Final Results From Posoleucel Study In Kidney Transplant Recipients With BK Viremia, Shares Fall
- ByBenzinga-
AlloVir Inc (NASDAQ: ALVR) announced the final results from a Phase 2 study of posoleucel for BK viremia (BKV) in adult kidney transplant recipients. The data support the safety...